Comprehensive Stock Comparison
Compare BlackRock Technology and Private Equity Term Trust (BTX) vs Eli Lilly and Company (LLY) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  LLY | 32.0% revenue growth vs BTX's -81.1% |
| Value | LLY | Lower P/E (29.4x vs 38.9x) |
| Quality / Margins |  BTX | 87.7% net margin vs LLY's 31.0% |
| Stability / Safety | LLY | Beta 0.65 vs BTX's 1.16 |
| Dividends | BTX | 12.9% yield, 1-year raise streak, vs LLY's 0.5% |
| Momentum (1Y) | LLY | +8.6% vs BTX's +6.8% |
| Efficiency (ROA) | LLY | 16.0% ROA vs BTX's 1.8%, ROIC 33.7% vs 1.4% |
Who Each Stock Is For
Income & stability
LLYDividend streak 10 yrs, beta 0.65, yield 0.5%
Growth exposure
LLYRev growth 32.0%, EPS growth 101.9%, 3Y rev CAGR 16.7%
Long-term compounding (10Y)
LLY13.2% 10Y total return vs BTX's -45.5%
Sleep-well-at-night portfolio
LLYLower volatility, beta 0.65, current ratio 1.15x
Defensive / Recession hedge
LLYBeta 0.65, yield 0.5%, current ratio 1.15x
Business Model
What each company does and how it makes money
BlackRock Technology and Private Equity Term Trust is a closed-end investment fund that pools investor capital to invest primarily in mid- and small-capitalization growth companies in the technology and healthcare sectors. It generates returns through capital appreciation and dividend income from its equity portfolio, with performance tied to the success of its underlying investments. The fund's key advantage is BlackRock's extensive research capabilities and access to innovative companies that traditional investors might overlook.
Eli Lilly is a global pharmaceutical company that discovers, develops, and markets innovative medicines for serious diseases like diabetes, cancer, and autoimmune disorders. It generates revenue primarily from drug sales — with diabetes treatments like Trulicity and Mounjaro contributing over 50% of revenue — and from oncology and immunology products. The company's competitive advantage lies in its deep research and development capabilities, particularly in diabetes and obesity treatments where it has established a strong patent-protected portfolio.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
LLY 3BTX 2BTX4/4 metricsBTX5/5 metricsLLY5/8 metricsLLY5/6 metricsLLY2/2 metricsLLY leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). BTX leads in 2 (Financial Metrics, Valuation Metrics). 1 tied.
Financial Metrics (TTM)
LLY is the larger business by revenue, generating $59.4B annually — 1460.3x BTX's $41M. BTX is the more profitable business, keeping 87.7% of every revenue dollar as net income compared to LLY's 31.0%.
| Metric | BTXBlackRock Technol… | LLYEli Lilly and Com… |
|---|---|---|
| RevenueTrailing 12 months | $41M | $59.4B |
| EBITDAEarnings before interest/tax | — | $28.6B |
| Net IncomeAfter-tax profit | — | $18.4B |
| Free Cash FlowCash after capex | — | $9.0B |
| Gross MarginGross profit ÷ Revenue | +100.0% | +83.0% |
| Operating MarginEBIT ÷ Revenue | +87.7% | +45.0% |
| Net MarginNet income ÷ Revenue | +87.7% | +31.0% |
| FCF MarginFCF ÷ Revenue | +6.8% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +53.9% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +4.8% |
Valuation Metrics
At 38.9x trailing earnings, BTX trades at a 55% valuation discount to LLY's 85.7x P/E. On an enterprise value basis, BTX's 21.6x EV/EBITDA is more attractive than LLY's 48.2x.
| Metric | BTXBlackRock Technol… | LLYEli Lilly and Com… |
|---|---|---|
| Market CapShares × price | $773M | $898.2B |
| Enterprise ValueMkt cap + debt − cash | $773M | $928.6B |
| Trailing P/EPrice ÷ TTM EPS | 38.94x | 85.70x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 29.43x |
| PEG RatioP/E ÷ EPS growth rate | — | 13.94x |
| EV / EBITDAEnterprise value multiple | 21.64x | 48.19x |
| Price / SalesMarket cap ÷ Revenue | 18.99x | 19.94x |
| Price / BookPrice ÷ Book value/share | 0.80x | 63.57x |
| Price / FCFMarket cap ÷ FCF | 2.79x | 2168.03x |
Profitability & Efficiency
LLY delivers a 77.2% return on equity — every $100 of shareholder capital generates $77 in annual profit, vs $2 for BTX. On the Piotroski fundamental quality scale (0–9), LLY scores 6/9 vs BTX's 3/9, reflecting solid financial health.
| Metric | BTXBlackRock Technol… | LLYEli Lilly and Com… |
|---|---|---|
| ROE (TTM)Return on equity | +1.9% | +77.2% |
| ROA (TTM)Return on assets | +1.8% | +16.0% |
| ROICReturn on invested capital | +1.4% | +33.7% |
| ROCEReturn on capital employed | +1.8% | +40.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | — | 2.36x |
| Net DebtTotal debt minus cash | $0 | $30.4B |
| Cash & Equiv.Liquid assets | — | $3.3B |
| Total DebtShort + long-term debt | $0 | $33.6B |
| Interest CoverageEBIT ÷ Interest expense | 2313.25x | 26.09x |
Total Returns (with DRIP)
A $10,000 investment in LLY five years ago would be worth $49,693 today (with dividends reinvested), compared to $5,453 for BTX. Over the past 12 months, LLY leads with a +8.6% total return vs BTX's +6.8%. The 3-year compound annual growth rate (CAGR) favors LLY at 47.3% vs BTX's 5.8% — a key indicator of consistent wealth creation.
| Metric | BTXBlackRock Technol… | LLYEli Lilly and Com… |
|---|---|---|
| YTD ReturnYear-to-date | +0.5% | -6.9% |
| 1-Year ReturnPast 12 months | +6.8% | +8.6% |
| 3-Year ReturnCumulative with dividends | +18.3% | +219.8% |
| 5-Year ReturnCumulative with dividends | -45.5% | +396.9% |
| 10-Year ReturnCumulative with dividends | -45.5% | +1316.4% |
| CAGR (3Y)Annualised 3-year return | +5.8% | +47.3% |
Risk & Volatility
LLY is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than BTX's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | BTXBlackRock Technol… | LLYEli Lilly and Com… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | 0.65x |
| 52-Week HighHighest price in past year | $7.50 | $1133.95 |
| 52-Week LowLowest price in past year | $5.10 | $623.78 |
| % of 52W HighCurrent price vs 52-week peak | +88.3% | +88.5% |
| RSI (14)Momentum oscillator 0–100 | 47.3 | 44.8 |
| Avg Volume (50D)Average daily shares traded | 908K | 3.0M |
Analyst Outlook
For income investors, BTX offers the higher dividend yield at 12.93% vs LLY's 0.52%.
| Metric | BTXBlackRock Technol… | LLYEli Lilly and Com… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $1214.28 |
| # AnalystsCovering analysts | — | 44 |
| Dividend YieldAnnual dividend ÷ price | +12.9% | +0.5% |
| Dividend StreakConsecutive years of raises | 1 | 10 |
| Dividend / ShareAnnual DPS | $0.86 | $5.18 |
| Buyback YieldShare repurchases ÷ mkt cap | +12.0% | +0.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 21 | Mar 26 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | 100 | 33.57 | -66.4% |
| Eli Lilly and Compa… (LLY) | 100 | 549.54 | +449.5% |
Eli Lilly and Compa… (LLY) returned +397% over 5 years vs BlackRock Technolog… (BTX)'s -45%. A $10,000 investment in LLY 5 years ago would be worth $49,693 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | $-640M | $41M | +106.4% |
| Eli Lilly and Compa… (LLY) | $20.0B | $45.0B | +125.7% |
Eli Lilly and Company's revenue grew from $20.0B (2015) to $45.0B (2024) — a 9.5% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | 100.1% | 87.7% | -12.4% |
| Eli Lilly and Compa… (LLY) | 12.1% | 23.5% | +94.8% |
Eli Lilly and Company's net margin went from 12% (2015) to 24% (2024).
Chart 4P/E Ratio History — 7 Years
| Stock | 2018 | 2024 | Change |
|---|---|---|---|
| Eli Lilly and Compa… (LLY) | 37 | 65.9 | +78.1% |
Eli Lilly and Company has traded in a 15x–101x P/E range over 7 years; current trailing P/E is ~86x.
Chart 5EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | -2.58 | 0.17 | +106.6% |
| Eli Lilly and Compa… (LLY) | 2.18 | 11.71 | +437.2% |
Eli Lilly and Company's EPS grew from $2.18 (2015) to $11.71 (2024) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
BlackRock Technology and Private Equity Term Trust generated $277M FCF in 2024 (+106% vs 2021). Eli Lilly and Company generated $414M FCF in 2024 (-92% vs 2021).
BTX vs LLY: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BTX or LLY a better buy right now?
BlackRock Technology and Private Equity Term Trust (BTX) offers the better valuation at 38.9x trailing P/E, making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BTX or LLY?
On trailing P/E, BlackRock Technology and Private Equity Term Trust (BTX) is the cheapest at 38.9x versus Eli Lilly and Company at 85.7x.
03Which is the better long-term investment — BTX or LLY?
Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +396.9%, compared to -45.5% for BlackRock Technology and Private Equity Term Trust (BTX). A $10,000 investment in LLY five years ago would be worth approximately $50K today (assuming dividends reinvested). Over 10 years, the gap is even starker: LLY returned +1316% versus BTX's -45.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BTX or LLY?
By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.65β versus BlackRock Technology and Private Equity Term Trust's 1.16β — meaning BTX is approximately 79% more volatile than LLY relative to the S&P 500.
05Which has better profit margins — BTX or LLY?
BlackRock Technology and Private Equity Term Trust (BTX) is the more profitable company, earning 87.7% net margin versus 23.5% for Eli Lilly and Company — meaning it keeps 87.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTX leads at 87.7% versus 38.9% for LLY. At the gross margin level — before operating expenses — BTX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BTX or LLY?
All stocks in this comparison pay dividends. BlackRock Technology and Private Equity Term Trust (BTX) offers the highest yield at 12.9%, versus 0.5% for Eli Lilly and Company (LLY).
07Is BTX or LLY better for a retirement portfolio?
For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65), 0.5% yield, +1316% 10Y return). Both have compounded well over 10 years (LLY: +1316%, BTX: -45.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BTX and LLY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: BTX is a small-cap income-oriented stock; LLY is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.